FibroGen, headquartered in San Francisco, focuses on developing novel therapeutics for cancer and anemia, with key products including Pamrevlumab and Roxadustat. The company went public on November 14, 2014, and employs 486 staff.
Thane Wettig bought 145,000 shares of FGEN on 24 March at $0.35 per share, worth a total of $51K. They now own 543,329 FGEN shares, or a 36% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
